Form 4 for VNRX VOLITIONRX LTD

Accepted 2025-10-15 00:00:00 ET · period of report 2025-10-14 · accession 0001477932-25-007588 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-10-15	2025-10-14	VNRX	Reynolds Cameron John	Pres, CEO, Dir	P - Purchase	$0.51	+110.0K	2.53M	+5%	+$56.1K
D	2025-10-15	2025-10-14	VNRX	Reynolds Cameron John	Pres, CEO, Dir	P - Purchase	$0.01	+110.0K	110.0K	New	+$1,100

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-10-14	P	A	110,000	$0.51	2,534,847	D	—	—	(F1) The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant.
2	Derivative	Warrant (Right to Buy)	2025-10-14	P	A	110,000	$0.01	110,000	D	$0.6 · 2025-10-14 to 2030-10-14	110,000 Common Stock	(F1) The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant.